New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
09:02 EDTAMGNAmgen announces analysis results of Phase 3 trial of talimogene laherparepvec
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor. Results showed that, while the primary end point of durable response rate was met, the secondary endpoint of OS was not met, although there was a strong trend in favor of talimogene laherparepvec. The estimated OS hazard ratio and improvement in median OS were similar to what was previously reported at the interim OS analysis. The most frequent adverse events observed in this trial were fatigue, chills and pyrexia. The most common serious adverse events include disease progression, cellulitis and pyrexia.
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
09:20 EDTAMGNInsulet weakness creates buying opportunity, says Wedbush
Wedbush believes that Insulet's growth should accelerate as the year progresses, driven by increased adoption of its unique, programmable insulin pump and the launch of Amgen's (AMGN) Neulasta On-Body Delivery System.
April 15, 2015
18:56 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTAMGNAmgen confirms FDA approval of Corlanor
Subscribe for More Information
16:40 EDTAMGNFDA approves Amgen's Corlanor to treat heart failure
Subscribe for More Information
April 6, 2015
05:19 EDTAMGNAmgen announces EC approval of Vectibix in combination with Folfiri
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use